Table 2. AFT Model to Predict Progression-Free Survival Fig 2. Effect of GETNE-TRASGU (Spanish Group of Neuroendocrine and Endocrine Tumors–Treated With Analog of Somatostatin in ...

Everolimus is a well-established therapeutic option for pancreatic neuroendocrine tumors (pNETs) but resistance is common ... groups and patients were identified as smokers by history (Table 1).

Foundation successfully hosted its 4th ICPO Forum for Theranostics in Precision Oncology on May 15 & 16, 2025 in Garching ...

Q1 2025 Earnings Call Transcript May 13, 2025 Exelixis, Inc. beats earnings expectations. Reported EPS is $0.55, expectations ...

Over 220 experts from around the globe came together to shape the future of radiotheranostics for better cancer patient outcomes Wiesbaden - May 26, 2025 - The International Centers for Precision ...

Welireg marks the first FDA-approved non-surgical treatment option for locally advanced, unresectable, or metastatic ...

This sentence previously stated: “Primary tumors originating in the rectum, histologic types 8240 and 8510, surgery, and chemotherapy were considered protective factors in prognosis (Table 4 ...

Several strategies have been used to inhibit VEGF signaling (Table). Broadly ... hepatocellular carcinoma, colorectal cancer, gastrointestinal stromal tumor, pancreatic neuroendocrine tumor, soft ...

A new combination therapy that pairs a radiopharmaceutical (177Lu-DOTATATE) with a DNA-repair blocker (olaparib) has been ...

A new combination therapy that pairs a radiopharmaceutical (177 Lu-DOTATATE) with a DNA-repair blocker (olaparib) has been deemed feasible and tolerable for neuroendocrine cancer patients.